ARTICLE | Clinical News
Micrologix Phase II acne results
November 30, 2001 8:00 AM UTC
Micrologix (TSE:MBI; MGIXF) said its MBI 594AN topical Bactolysin antimicrobial cationic peptide gave a 32% reduction in total lesions versus 14% for placebo in a double-blind Phase II study in 75 pat...